A clinical trial to prevent renal toxicity of cisplatin by administration of bismuth subnitrate and fosfomycin

The effect of treatment with bismuth subnitrate (BSN) and fosfomycin (FOM) for prevention of renal toxicity of the cisplatin (CDDP) was examined in 41 head and neck cancer patients.Patients were classified into three groups:1) Hydration group consisted of 20 patients who were treated by CDDP with hydration and mannitol. 2) BSN group consisted of 14 patients who were treated by CDDP and BSN with hydration and mannitol. 3) BSN·FOM group, consisted of 7 patients who were treated by CDDP, BSN and FOM with hydration and mannitol.Scrum BUN, creatinine and urinary NAG were abnormally high in hydration group, but almost normal in BSN and BSN·EFOM groups. No renal toxicity was shown in BSN and BSN·EFOM groups.